291 related articles for article (PubMed ID: 27206567)
1. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
Nguyen CT; Zhou S; Shanahan W; Fain R
Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
[TBL] [Abstract][Full Text] [Related]
2. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability review of lorcaserin in clinical trials.
Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
[TBL] [Abstract][Full Text] [Related]
4. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM; Berlie HD
Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
[TBL] [Abstract][Full Text] [Related]
5. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of lorcaserin in the management of obesity.
Hess R; Cross LB
Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S
Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931
[TBL] [Abstract][Full Text] [Related]
8. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
[TBL] [Abstract][Full Text] [Related]
9. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
Nigro SC; Luon D; Baker WL
Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
[TBL] [Abstract][Full Text] [Related]
10. 2 new drugs for weight loss.
Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
[No Abstract] [Full Text] [Related]
11. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.
Nesto R; Fain R; Li Y; Shanahan W
Postgrad Med; 2016 May; 128(4):364-70. PubMed ID: 27116910
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Bohula EA; Wiviott SD; McGuire DK; Inzucchi SE; Kuder J; Im K; Fanola CL; Qamar A; Brown C; Budaj A; Garcia-Castillo A; Gupta M; Leiter LA; Weissman NJ; White HD; Patel T; Francis B; Miao W; Perdomo C; Dhadda S; Bonaca MP; Ruff CT; Keech AC; Smith SR; Sabatine MS; Scirica BM;
N Engl J Med; 2018 Sep; 379(12):1107-1117. PubMed ID: 30145941
[TBL] [Abstract][Full Text] [Related]
13. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.
Handelsman Y; Fain R; Wang Z; Li X; Fujioka K; Shanahan W
Postgrad Med; 2016 Nov; 128(8):740-746. PubMed ID: 27659698
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
[TBL] [Abstract][Full Text] [Related]
15. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
Scirica BM; Bohula EA; Dwyer JP; Qamar A; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Murphy SA; Im K; Leiter LA; Gupta M; Patel T; Miao W; Perdomo C; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
Circulation; 2019 Jan; 139(3):366-375. PubMed ID: 30586726
[TBL] [Abstract][Full Text] [Related]
16. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
[TBL] [Abstract][Full Text] [Related]
17. Role of impulsivity and reward in the anti-obesity actions of 5-HT
Higgins GA; Zeeb FD; Fletcher PJ
J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522
[TBL] [Abstract][Full Text] [Related]
18. Lorcaserin Hcl for the treatment of obesity.
Shukla AP; Kumar RB; Aronne LJ
Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
[TBL] [Abstract][Full Text] [Related]
19. Lorcaserin. In obesity: unacceptable risks.
Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
[TBL] [Abstract][Full Text] [Related]
20. Directly Observable Behavioral Effects of Lorcaserin in Rats.
Serafine KM; Rice KC; France CP
J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]